Factors Associated With Nirsevimab Uptake in Healthy Newborns
- Elena Aragona; Veronika Shabanova; Jaspreet Loyal
Access Resources
About
This research brief discusses a study that looks at factors affecting the use of nirsevimab, a new antibody for RSV, in newborns. It explains how 57% of babies received it during a study period. Factors like insurance type, language spoken at home, and being first-time parents influenced uptake. Babies whose parents refused other common newborn treatments were more likely to miss nirsevimab too. The study found differences between hospitals and suggested further research to understand parental concerns better. It also noted that Spanish-speaking families showed higher acceptance despite general vaccine hesitancy trends among them.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.